A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg administered orally once daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
The purpose of this research study is to : 1. Test the safety and effectiveness of treatment with two doses BI 10773 in subjects with Type 2 diabetes and high cardiovascular risk. 2. To compare BI 10773 to placebo (inactive substance) by assessing the number of Cardiovascular Event endpoints such as cardiovascular death, nonfatal stroke and nonfatal myocardial infarction. (Enrolling in Jacksonville, FL)
Principal InvestigatorKent Wehmeier, Clinical Associate Professor ( & Chief )
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.